The American free market is the world’s cradle for medical innovation, giving rise to the latest advances in medicine such as novel platforms for gene editing, cancer immunotherapy, and percutaneous cardiac valve intervention.
Antimicrobial resistance (AMR) represents an urgent clinical and economic crisis for the American health care system. Each year, more than 2 million Americans are infected by bacteria that are resistant to existing antibiotic drugs, resulting in thousands of deaths annually.
One of our priorities at CMS is to identify innovative approaches to improving care for our beneficiaries. Too often we’ve heard about the challenges beneficiaries, families, and caregivers face navigating health care, especially when it comes to transitioning between care settings.
Health care: American’s favorite debate topic. While there is much to debate, we can all agree that the patient-provider relationship has been strained by unnecessary regulations and reporting requirements.

History tells us that when monopolies form prices rise, innovation sputters, and consumers suffer.  It is curious why advocates for single-payer, government-run solutions ignore this reality, as if healthcare is somehow exempt from economic forces.  Turning our healthcare payment system into a government-run monopoly is a recipe for high costs and long wait times.